Login / Register Order My Items
Contact Us
800.227.0627
Contact Us Quote Order Login / Register

Cleavable Linker Oligonucleotide Modification

Trigger-cleavable linker strategies for oligo–drug conjugates (ODCs) with defined attachment sites and fit-for-purpose analytics.

What we build: cleavable linker installation for siRNA, ASO, DNA, PNA, and PMO constructs—supporting redox (disulfide), pH-labile, enzyme-cleavable, ROS-responsive, and self-immolative release models.

Request a Quote Browse linker classes
Talk to a chemist Request a quote
Overview When to use Linker classes Attachment sites Selection guide Workflow QC Reading FAQ Contact

Overview

What is cleavable linker oligonucleotide modification?

Cleavable linker oligonucleotide modification refers to installing a trigger-responsive linker onto an oligonucleotide scaffold so that a small-molecule payload can be released under defined biological conditions. In oligo–drug conjugates (ODCs), linker engineering often determines circulating stability, intracellular release kinetics, and the practical balance between efficacy and tolerability.

A well-designed cleavable linker remains intact through synthesis, purification, and circulation, then cleaves in the intended compartment (e.g., endosome/lysosome for pH triggers; cytosol for redox triggers; enzyme-rich compartments for protease triggers). Where required, self-immolative spacers can ensure the payload is released in a native or pharmacologically active form.

Disulfide (redox) pH-labile Enzyme-cleavable ROS-responsive Self-immolative spacers
Cleavable linker ODC architecture showing oligonucleotide, trigger-cleavable linker, self-immolative spacer, and payload release
Conceptual architecture: oligonucleotide + trigger-cleavable linker ± self-immolative spacer + payload (drug or delivery-active small molecule).
Request a Quote Linker selection guide

When to use a cleavable linker

Payload requires release

Many cytotoxic oncology drugs and some antibiotics require release to achieve full activity.

  • Free-drug pharmacophore needed
  • Reduces steric masking
  • Enables triggered activation
Control systemic exposure

Linker stability can help limit off-target activity prior to internalization.

  • Stability in serum/plasma
  • Release in target compartment
  • Mechanism-aligned safety design
Structure–function screening

Compare stable vs cleavable variants to identify the dominant driver of potency.

  • Position/spacer variants
  • Different trigger chemistries
  • Matched analytical readouts
When non-cleavable is better

Non-cleavable linkers are often preferred when the payload is a delivery modifier (PK/uptake tuning) or when activity is retained while tethered. We can help you decide by mapping the payload’s mechanism to the intended intracellular compartment and release requirement.

Cleavable linker classes for ODCs

Expand each linker class for triggers, practical notes, and common use cases in oligo–drug conjugation.

S–S linkers cytosolic release siRNA / ASO compatible

Disulfide linkers are designed to remain stable extracellularly and cleave under the more reducing intracellular environment. Cleavage rate is influenced by steric shielding, spacer length, and local microenvironment.

Trigger Typical placement Design notes
Reductive cytosol 5′/3′ termini; internal positions (determined by the selected architecture) Consider spacer length to minimize aggregation; define whether a residual fragment on the payload is acceptable.

hydrazone acetal/ketal endosomal release

pH-labile linkers can enable release in acidic compartments. Serum stability must be assessed to avoid premature hydrolysis. Buffer conditions during handling and purification should also be selected to protect the linkage.

Trigger Examples Design notes
Acidic pH Hydrazone; acetal/ketal motifs (dependent on the payload’s functional groups) Choose the handle so the pharmacophore remains intact; plan stability profiling early.

protease Val–Cit / Val–Ala self-immolative

Protease-cleavable linkers are often paired with self-immolative spacers to release the payload in a native form. Oligonucleotide trafficking must be considered so the construct reaches enzyme-rich compartments.

Trigger Examples Design notes
Lysosomal proteases Protease-sensitive peptide motifs (dependent on the payload’s functional groups) Spacer and linker accessibility drive cleavage; specify whether self-immolation is required.

thioketal boronic ester advanced screening

ROS-responsive linkers are used in more exploratory programs where oxidative stress is leveraged as a trigger. Feasibility depends on payload chemistry, handle availability, and stability requirements.

self-immolative native drug release two-stage cleavage

Self-immolative spacers are used when you need a clean payload release after the trigger event. They are typically combined with redox or enzyme triggers and chosen to minimize residual linker fragments on the released drug.

Attachment sites and oligo-specific constraints

5′ attachment

Common for terminal conjugation when compatible with the oligo’s biological requirements.

  • 5′-amine / 5′-thiol / 5′-azide
  • Spacer options available
  • Defined 1:1 loading typical
3′ attachment

Often used when 5′ features must be preserved (e.g., siRNA antisense requirements).

  • 3′-amine / 3′-thiol / 3′-azide
  • Good for hydrophobic payloads with spacers
  • Compatible with click or thiol chemistries
Internal attachment

Used when terminal attachment is constrained; placement is selected to preserve function.

  • Modified base/backbone positions
  • Supports defined architecture variants
  • Best with early design review
siRNA and ASO notes

For duplex siRNA, specify strand and terminus. Delivery-active payloads are often placed on the sense strand while preserving antisense features needed for RISC loading. For ASOs, attachment is chosen to minimize interference with RNase H recruitment or steric-block function (format-dependent).

Linker selection guide

A practical selection starts with the intended compartment of release and the payload’s need for liberation. We typically evaluate: payload functional groups, required release trigger, solubility/handling constraints, and how attachment site affects oligo function.

Goal Trigger Linker class Notes
Cytosolic release Redox Disulfide Common for intracellular release models; spacer/shielding influences kinetics.
Endosomal/lysosomal release Acidic pH Hydrazone / acetal-ketal Assess serum stability; handling conditions should protect the linkage.
Protease-triggered release Enzyme Protease-cleavable + self-immolative Requires trafficking to enzyme-rich compartments; define “clean release” requirement.
Exploratory triggers ROS ROS-responsive motifs Feasibility depends on payload chemistry and stability targets.
Upon review of the payload structure, we can recommend an appropriate handle and linker strategy and provide screening variants (position/spacer/trigger).

Workflow

Design review

Oligo modality/sequence • payload structure • trigger and compartment • attachment site & spacer.

Synthesis & conjugation

Site-defined installation • stable handling • trigger-cleavable linkage selection.

Purification & QC

HPLC/UPLC • LC-MS when structurally compatible • optional release profiling.

Quality control & deliverables

Standard QC
  • Analytical HPLC/UPLC purity profile
  • Identity confirmation by LC-MS when structurally compatible
  • COA + method summary
Linker integrity
  • Route controls to preserve cleavable linkage
  • Handle planning to minimize mixtures
  • Optional stability notes (determined by the selected architecture)
Optional release profiling

Trigger-relevant challenge conditions and analytical readouts aligned to your decision criteria.

FAQ

When should I use a cleavable linker in an ODC?

Use a cleavable linker when payload activity requires intracellular release or when tethering sterically masks the pharmacophore. Linker choice is driven by the intended trigger and the compartment where release should occur.

Which linker types are most common for siRNA and ASO?

Common strategies include disulfide (redox-cleavable), pH-labile linkers, enzyme-cleavable motifs paired with self-immolative spacers, and trigger-cleavable self-immolative designs.

Where can the linker be installed on the oligo?

Cleavable linkers can be installed at 5′/3′ termini or internal positions. For duplex siRNA, placement is often on the sense strand to preserve antisense strand requirements for RISC loading.

How do you confirm linker integrity and release?

We confirm intact conjugates by HPLC/UPLC and LC-MS when structurally compatible. Release can be profiled under trigger-relevant conditions using analytical readouts aligned to your decision criteria.

More FAQ'sAll FAQ's

Contact & quote request

For the fastest quote, share your oligo modality/sequence, payload structure (or catalog number), intended trigger (redox/pH/enzyme/ROS), preferred attachment site (and strand/terminus for siRNA), desired quantity/purity, and the release hypothesis (if known).

Fast quote checklist
  • Oligo modality: siRNA / ASO / DNA / aptamer / PNA / PMO
  • Sequence(s) and strand info (for siRNA duplex)
  • Trigger model: redox / pH / enzyme / ROS / self-immolative
  • Preferred attachment site: 5′ / 3′ / internal + handle (amine/thiol/azide/alkyne/DBCO)
  • Payload name + structure (or catalog number) and known functional groups
  • Quantity (mg) + purity target + intended use

If you’re unsure which trigger is best, send the payload structure—route selection is driven by functional groups and stability constraints.

Fastest path
Request a Quote Selection guide

We review feasibility, define an attachment strategy, outline purification/QC, and provide a detailed quotation.

Typical applications

Oncology ODC release models
  • siRNA–cytotoxic payload conjugates where free-drug release is required
  • ASO–drug conjugates with trigger-cleavable release
  • Stable vs cleavable head-to-head screening sets
Antibiotic–oligo conjugates
  • Antibiotic payload attachment for intracellular delivery concepts
  • Cleavable vs tethered activity evaluation
  • Spacer tuning to manage polarity/handling
Delivery and escape programs
  • Endosome/lysosome pH-triggered release designs
  • Redox-cleavable cytosolic release architectures
  • Self-immolative spacer programs for “clean” payload liberation
Screening-ready variant sets

Many programs benefit from a small, rational library: attachment site (5′/3′/internal), spacer length, and trigger class (redox/pH/enzyme) varied while keeping the payload constant. This accelerates structure–function decisions.

Recommended reading

  1. [1]Roberts T.C., Langer R., Wood M.J.A. (2020). Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery.
  2. [2]Juliano R. (2016). The delivery of therapeutic oligonucleotides. Nucleic Acids Research.
  3. [3]Prakash T.P., & colleagues (2019). Oligonucleotide conjugates and delivery approaches. Annual Review of Pharmacology and Toxicology.
  4. [4]Reviews on cleavable linker technologies and self-immolative spacers in drug conjugates. Nature Reviews Drug Discovery.
  5. [5]Stimuli-responsive linkers for controlled release. Chemical Reviews.

If you share your payload and trigger model, we can tailor the reference set to your linker class and analytical release plan.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links